Limited Product Portfolio & Acquisition Risk: The company's future growth heavily depends on its ability to acquire new products and expand its current portfolio, which is subject to availability and competitive bidding, posing a risk if suitable assets cannot be secured.

Regulatory & Approval Risk: Products, whether existing or acquired, must receive and maintain necessary regulatory approvals from health authorities, which can be a lengthy, costly, and uncertain process, potentially delaying or preventing market entry.

Market Competition Risk: Knight Therapeutics operates in a highly competitive pharmaceutical market, facing larger, more established companies with greater resources for product development and marketing, which could limit market share and profitability.